Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Income Statement - Annual

Dec '20

Dec '21

Dec '22

Dec '23

Dec '24

LTM

Dec '25 (E)

Dec '26 (E)

Dec '27 (E)

Income Statement	LTM	Dec '24
Selling, General & Administrative Expenses	112	89.2
General and Administrative
Research & Development Expenses	680.6	795.9
Research and Development
Operating Profit	-792.6	-885.1
Loss from Operations
Interest and Investment Income	—	—
Gain from Equity Method Investment
Non-Operating Income	13.6	39.4
Other Expense, Net
Total Non-Operating Income	13.6	39.4
Income Before Provision for Income Taxes	-779	-845.7
Loss Before Provision for Income Taxes
Provision for Income Taxes	1.1	0.7
Provision for Income Taxes
Consolidated Net Income	-780.1	-846.4
Net Income Attributable to Common Shareholders	-780.1	-846.4
Net Loss
Basic EPS	-7.6	-9.3
Diluted EPS	-7.6	-9.3
Basic Weighted Average Shares Outstanding	102.8	91.2
Diluted Weighted Average Shares Outstanding	102.8	91.2
Total Shares Outstanding	105.9	101.2
EBITDA	-782.8	-877.3
Effective Tax Rate	-0.1%	-0.1%